[1]陈礼林,谢丽君,张海波,等.靶向肽结合131I-PAMAM(G5.0)抑制甲状腺髓样癌细胞增殖的研究[J].国际放射医学核医学杂志,2017,41(5):307-313.[doi:10.3760/cma.j.issn.1673-4114.2017.05.001]
　Chen Lilin,Xie Lijun,Zhang Haibo,et al.Effects of targeted peptide-conjugated 131I-PAMAM (G5.0) on the inhibition of medullary thyroid carcinoma cells proliferation[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):307-313.[doi:10.3760/cma.j.issn.1673-4114.2017.05.001]
点击复制

靶向肽结合131I-PAMAM(G5.0)抑制甲状腺髓样癌细胞增殖的研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
41
期数:
2017年第5期
页码:
307-313
栏目:
论著
出版日期:
2017-09-25

文章信息/Info

Title:
Effects of targeted peptide-conjugated 131I-PAMAM (G5.0) on the inhibition of medullary thyroid carcinoma cells proliferation
作者:
陈礼林;  谢丽君;  张海波;  杨洪文;  何蕊;  冯成涛;  朱高红
650032, 昆明医科大学第一附属医院核医学科
Author(s):
Chen Lilin;  Xie Lijun;  Zhang Haibo;  Yang Hongwen;  He Rui;  Feng Chengtao;  Zhu Gaohong
Department of Nuclear Medicine, the First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
关键词:
碘放射性同位素; 分子探针; 甲状腺髓样癌; 聚酰胺-胺; 丝氨酸-精氨酸-谷氨酸-丝氨酸-脯氨酸-组氨酸-脯氨酸
Keywords:
Iodine radioisotopes; Molecular probes; Medullary thyroid carcinoma; Polyami-doamine; Ser-Arg-Glu-Ser-Pro-His-Pro
DOI:
10.3760/cma.j.issn.1673-4114.2017.05.001
摘要:
目的 研究131I标记靶向肽丝氨酸-精氨酸-谷氨酸-丝氨酸-脯氨酸-组氮酸-脯氨酸（SRESPHP）（简称SR）修饰的第五代聚酰胺-胺（PAMAM（G5.0））的体外性质及其作为甲状腺髓样癌细胞靶向探针的可行性。方法 用氯胺T法进行PAMAM（G5.0）-SR和PAMAM（G5.0）的131I标记，通过薄层层析法分别测定所制备的两种探针的标记率及稳定性，并考察131I标记物的脂水分配系数；通过阻断摄取实验分别考察两种探针的靶向性；计算两种探针对细胞的半数致死剂量并分析其对细胞生长的影响。采用GraphPad Prism 5.01分析软件对符合正态分布及方差齐性的数据进行样本t检验。结果 131I-PAMAM（G5.0）-SR和131I-PAMAM（G5.0）的标记率均大于70%，纯化后的放化纯度均大于90%。两种探针在体外PBS体系中的稳定性好，且均显示出良好的水溶性。细胞阻断实验结果显示，加入PAMAM（G5.0）-SR阻断的131I-PAMAM（G5.0）-SR细胞摄取率明显降低，差异均有统计学意义（t=7.315、22.590和22.570，均P<0.01），提示131I-PAMAM（G5.0）-SR对细胞具有较好的靶向性。131I-PAMAM（G5.0）-SR的细胞半数致死剂量为513.6 kBq/mL。细胞摄取实验结果显示，随着时间的延迟，细胞对半数致死剂量下的131I-PAMAM（G5.0）-SR的摄取逐渐降低，但在48 h细胞摄取出现上升的现象，随后细胞摄取再次下降。结论 131I-PAMAM（G5.0）-SR具有良好的生物学性质，可靶向甲状腺髓样癌细胞并抑制细胞增殖。
Abstract:
Objective To incorporate 131I i nto the fifth generation polyamidoamine(PAMAM (G5.0)) with the targeting peptide Ser-Arg-Glu-Ser-Pro-His-Pro(SRESPHP)(SR for short) and observe the in vitro properties for the targeting probe of medullary carcinoma cells (MTCs). Methods PAMAM (G5.0)-SR and PAMAM(G5.0) were radiolabeled with 131I by chloramine T. Labeling yield and stability were determined by thin layer chromatography. Lipid -water partition coefficients were also evaluated. The targeting of the two types of 131I-radiotracers(131I-PAMAM(G5.0)-SR and 131I-PAMAM(G5.0)) was determined in a blocking uptake study where TT tumor cells were used. The median lethal dose of the two probes was then calculated. GraphPad Prism 5.01 analysis software was used to conduct a t-test for the data that fit the normal distribution and homogeneity of variance. Results The labeling yields of the two types of 131I radiotracers all exceeded 70%, and the radiochemical purity levels were higher than 90% after purification. The stability of the two probes in the PBS system was satisfactory, and both probes showed excellent water solubility. The results of the blocking uptake study on the TT cells showed that the cell uptake rate decreased significantly (t=7.315, 22.590, 22.570, all P<0.01) after the PAMAM (G5.0)-SR blocked the 131I-PAMAM (G5.0)-SR. This result indicated that 131I-PAMAM (G5.0)-SR achieved excellent targeting and that its median lethal dose was only 513.6 kBq/mL. The cell uptake results showed that the cell uptake rate of 131I-PAMAM (G5.0)-SR with a median lethal dose gradually decreased with time. However, cell uptake rate increased for 48 h before it decreased again. Conclusion 131I-PAMAM (G5.0)-SR can target medullary thyroid carcinoma cells and thus inhibit cell proliferation.

参考文献/References:

[1] Faggiano A, Milone F, Ramundo V, et al. A decrease of calcitonin serum concentations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal[J]. J Clin Endocrinol Metab, 2010, 95(9):E32-E36. DOI:10.1210/jc.2010- 0045.
[2] 董薇, 陈晓红. 甲状腺髓样癌研究进展[J]. 国际耳鼻咽喉头颈外科杂志, 2013, 37(1):42-46. DOI:10.3760/cma.j.issn.1673-4106. 2013.01.011. Dong W, Chen XH. Advances in medullary thyroid carcinoma[J]. Int J Otolaryngol Head Neck Surg, 2013, 37(1):42-46.
[3] Mukherjee SP, Lyng FM, Garcia A, et al. Mechanistic studies of in vitro cytotoxicity of poly(amidoamine) dendrimers in mammalian cells[J]. Toxicol Appl Pharmacol, 2010, 248(3):259-268. DOI:10. 1016/j.taap.2010.08.016.
[4] Kannan S, Kolhe P, Raykova V, et al. Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells[J]. J Biomater Sci Polym Ed, 2004, 15(3):311-330. DOI:10.1163/156856204322977201.
[5] Bokmann M, Hilken G, Schmidt A, et al. Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection[J]. Hum Gene Ther, 2005, 16(11):1267- 1275. DOI:10.1089/hum.2005.16.1267.
[6] Urbiola K, Blanco-Fernández L, Navarro G, et al. Evaluation of improved PAMAM-G5 conjugates for gene delivery targeted to the transferrin receptor[J]. Eur J Pharm Biopharm, 2015, 94:116-122. DOI:10.1016/j.ejpb.2015.05.007.
[7] 刘金剑, 刘鉴峰. 纳米材料在核医学中的应用[J]. 国际放射医学核医学杂志, 2010, 34(6):326-329. DOI:10.3760/cma.j.issn.1673- 4114,2010.06.002. Liu JJ, Liu JF. The applications of nanomaterials in nuclear medicine[J]. Int J Radiat Med Nucl Med, 2010, 34(6):326-329.
[8] Zeng Y, Kurokawa Y, Win-Shwe TT, et al. Effects of PAMAM dendrimers with various surface functional groups and multiple generations on cytotoxicity and neuronal differentiation using human neural progenitor cells[J]. J Toxicol Sci, 2016, 41(3):351- 370. DOI:10.2131/jts.41.351.
[9] He R, Wang HW, Su YL, et al. Incorporating 131I into a PAMAM (G5.0) dendrimer-conjugate:design of a theranostic nanosensor for medullary thyroid carcinama[J]. RSC Adv, 2017, 7:16181-16188. DOI:10.1039/C7RA00604G.
[10] Wang YA, Shen WW, Shi XY, et al. Alpha-Tocopheryl SuccinateConjugated G5 PAMAM dendrimer enables effective inhibition of ulcerative colitis[J/OL]. Adv Healthc Mater, 2017, 6(14):1700276[2017-08-15]. http://onlinelibrary.wiley.com/doi/10.1002/adhm.201700276/pdf.DOI:10.1002/adhm.201700276.
[11] Pourianazar NT, Mutlu P, Gunduz U. Bioapplications of poly (amidoamine) (PAMAM) dendrimers in nanomedicine[J/OL]. J Nanopart Res, 2014, 16:2342[2017-08-15]. https://www.researchgate.net/publication/266991692_bioapplications_of_polyamidoamine_pamam_dendrimers_in_nanomedicine.DOI:10.1007/s11051-014-2342-1.
[12] 李承霞, 李玮, 张富海, 等. 131I标记抗表皮生长因子受体抗体靶向性纳米载体治疗胶质母细胞瘤的可行性实验研究[J]. 中华放射医学与防护杂志, 2016, 36(3):161-167. DOI:10.3760/cma.j.issn. 0254-5098.2016.03.001. Li CX, Li W, Zhang FH, et al. Targeting therapeutic effect of radioiodine-labeled anti-EGFR binding nanoparticles on glioblastoma cells[J]. Chin J Radiol Med Prot, 2016, 36(3):161- 167.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]张晓,兰晓莉,胡帆,等.点击化学在分子影像学中的应用和进展[J].国际放射医学核医学杂志,2016,40(3):196.[doi:10.3760/cma.j.issn.1673-4114.2016.03.008]
　Zhang Xiao,Lan Xiaoli,Hu Fan,et al.Applications and advances of click chemistry in molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):196.[doi:10.3760/cma.j.issn.1673-4114.2016.03.008]
[3]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[4]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[5]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[6]解朋,黄建敏,张芳,等.99Tcm-MAG3-isoDGR-2C分子探针的制备与体内分布的实验研究[J].国际放射医学核医学杂志,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
　Xie Peng,Huang Jianmin,Zhang Fang,et al.Labeling MAG3-isoDGR-2C with 99Tcm and its biodistribution in mice[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):345.[doi:10.3760/cma.j.issn.1673-4114.2016.05.004]
[7]汪文霞,兰晓莉,张永学.HER2的表达及其分子影像的研究进展[J].国际放射医学核医学杂志,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
　Wang Wenxia,Lan Xiaoli,Zhang Yongxue.Research and development of HER2 expression molecular imaging[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):363.[doi:10.3760/cma.j.issn.1673-4114.2016.05.007]
[8]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[9]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[10]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(5):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]

备注/Memo

备注/Memo:
收稿日期:2017-08-15。
基金项目:国家自然科学基金（81360223）
通讯作者:朱高红,Email:1026909611@qq.com
更新日期/Last Update: 2017-09-25